PDUFA Apr 10, 2026: Replimune’s BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma | …
Explore the latest developments concerning PDUFA Apr 10,. PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma Replimune (NASDAQ:...









